{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:33:30Z","timestamp":1790674410836,"version":"4.1.0"},"reference-count":172,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018M3A9H4056536"],"award-info":[{"award-number":["2018M3A9H4056536"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Traditional influenza vaccines generate strain-specific antibodies which cannot provide protection against divergent influenza virus strains. Further, due to frequent antigenic shifts and drift of influenza viruses, annual reformulation and revaccination are required in order to match circulating strains. Thus, the development of a universal influenza vaccine (UIV) is critical for long-term protection against all seasonal influenza virus strains, as well as to provide protection against a potential pandemic virus. One of the most important strategies in the development of UIVs is the selection of optimal targeting antigens to generate broadly cross-reactive neutralizing antibodies or cross-reactive T cell responses against divergent influenza virus strains. However, each type of target antigen for UIVs has advantages and limitations for the generation of sufficient immune responses against divergent influenza viruses. Herein, we review current strategies and perspectives regarding the use of antigens, including hemagglutinin, neuraminidase, matrix proteins, and internal proteins, for universal influenza vaccine development.<\/jats:p>","DOI":"10.3390\/v13060973","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:35:05Z","timestamp":1621899305000},"page":"973","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeting Antigens for Universal Influenza Vaccine Development"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3451-0493","authenticated-orcid":false,"given":"Quyen-Thi","family":"Nguyen","sequence":"first","affiliation":[{"name":"College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0872-0147","authenticated-orcid":false,"given":"Young-Ki","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Korea"},{"name":"Zoonotic Infectious Diseases Research Center, Chungbuk National University, Cheongju 28644, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Asha, K., and Kumar, B. (2019). Emerging Influenza D Virus Threat: What We Know so Far!. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020192"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0042-6822(90)90186-U","article-title":"Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983","volume":"175","author":"Rota","year":"1990","journal-title":"Virology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2015.11.036","article-title":"Detection of influenza C virus but not influenza D virus in Scottish respiratory samples","volume":"74","author":"Smith","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/JVI.01662-19","article-title":"Murine model for the study of influenza D virus","volume":"94","author":"Oliva","year":"2020","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/21645515.2017.1377376","article-title":"Immune responses after live attenuated influenza vaccination","volume":"14","author":"Mohn","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e01065-19","DOI":"10.1128\/JVI.01065-19","article-title":"A live attenuated influenza vaccine elicits enhanced heterologous protection when the internal genes of the vaccine are matched to those of the challenge virus","volume":"94","author":"Smith","year":"2020","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0264-410X(93)90194-3","article-title":"Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987\/88","volume":"11","author":"Slepushkin","year":"1993","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/infdis\/168.4.881","article-title":"Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia","volume":"168","author":"Rudenko","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"30450","DOI":"10.2807\/1560-7917.ES.2017.22.4.30450","article-title":"Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015\/16 season","volume":"22","author":"Pebody","year":"2017","journal-title":"Eurosurveillance"},{"key":"ref_10","unstructured":"CDC. Centers for Disease Control Prevention (2020, November 12). Seasonal Flu Vaccine Effectiveness Studies, Available online: https:\/\/www.cdc.gov\/flu\/vaccines-work\/effectiveness-studies.htm."},{"key":"ref_11","unstructured":"WHO. World Health Organization (2020, November 12). Influenza (Seasonal). Fact Sheet. Available online: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Iacobucci, G. (2020). Covid-19: Risk of death more than doubled in people who also had flu, English data show. BMJ, 370.","DOI":"10.1136\/bmj.m3720"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.immuni.2017.09.007","article-title":"The Pathway to a Universal Influenza Vaccine","volume":"47","author":"Paules","year":"2017","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coi.2018.04.001","article-title":"Development of next generation hemagglutinin-based broadly protective influenza virus vaccines","volume":"53","author":"Nachbagauer","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2018.00123","article-title":"Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture","volume":"9","author":"Rajao","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sebastian, S., and Lambe, T. (2018). Clinical Advances in Viral-Vectored Influenza Vaccines. Vaccines, 6.","DOI":"10.3390\/vaccines6020029"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fimmu.2018.00600","article-title":"Novel Platforms for the Development of a Universal Influenza Vaccine","volume":"9","author":"Kumar","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14760584.2018.1541408","article-title":"Universal influenza vaccines: From viruses to nanoparticles","volume":"17","author":"Wang","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","article-title":"Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses","volume":"9","author":"Deng","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"01568","DOI":"10.3389\/fimmu.2018.01568","article-title":"A Review of DNA Vaccines Against Influenza","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Scorza, F.B., and Pardi, N. (2018). New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines, 6.","DOI":"10.3390\/vaccines6020020"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Darricarrere, N., Pougatcheva, S., Duan, X., Rudicell, R.S., Chou, T.H., DiNapoli, J., Ross, T.M., Alefantis, T., Vogel, T.U., and Kleanthous, H. (2018). Development of a Pan-H1 Influenza Vaccine. J. Virol., 92.","DOI":"10.1128\/JVI.01349-18"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3389\/fmicb.2019.01630","article-title":"Influenza vaccine with consensus internal antigens as immunogens provides cross-group protection against influenza A viruses","volume":"10","author":"Xie","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0042-6822(83)90465-8","article-title":"Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: Unmasking of cross-reactive HA2 determinants","volume":"126","author":"Graves","year":"1983","journal-title":"Virology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., Garcia-Sastre, A., and Palese, P. (2010). Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio, 1.","DOI":"10.1128\/mBio.00018-10"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"13434","DOI":"10.1128\/JVI.01429-12","article-title":"Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge","volume":"86","author":"Bommakanti","year":"2012","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.vaccine.2015.05.038","article-title":"Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses","volume":"33","author":"Wohlbold","year":"2015","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22666","DOI":"10.1038\/srep22666","article-title":"Stalking influenza by vaccination with pre-fusion headless HA mini-stem","volume":"6","author":"Valkenburg","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"200ra114","DOI":"10.1126\/scitranslmed.3006366","article-title":"Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease","volume":"5","author":"Khurana","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.1073\/pnas.1821317116","article-title":"Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics","volume":"116","author":"Winarski","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1128\/JVI.00137-12","article-title":"Influenza viruses expressing chimeric hemagglutinins: Globular head and stalk domains derived from different subtypes","volume":"86","author":"Hai","year":"2012","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/JVI.02598-15","article-title":"Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains","volume":"90","author":"Ryder","year":"2015","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.virol.2018.03.013","article-title":"Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin","volume":"518","author":"Korenkov","year":"2018","journal-title":"Virology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Nachbagauer, R., Kinzler, D., Choi, A., Hirsh, A., Beaulieu, E., Lecrenier, N., Innis, B.L., Palese, P., Mallett, C.P., and Krammer, F. (2016). A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines, 1.","DOI":"10.1038\/npjvaccines.2016.15"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1128\/JVI.03183-13","article-title":"H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge","volume":"88","author":"Krammer","year":"2014","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ermler, M.E., Kirkpatrick, E., Sun, W., Hai, R., Amanat, F., Chromikova, V., Palese, P., and Krammer, F. (2017). Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J. Virol., 91.","DOI":"10.1128\/JVI.00286-17"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104625","DOI":"10.1016\/j.yrtph.2020.104625","article-title":"Chimeric hemagglutinin supra-seasonal universal influenza vaccine candidates administered sequentially by the intramuscular route are locally and systemically well-tolerated in rabbits","volume":"113","author":"Destexhe","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-017-0026-4","article-title":"A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies","volume":"2","author":"Nachbagauer","year":"2017","journal-title":"NPJ Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liu, W.C., Nachbagauer, R., Stadlbauer, D., Strohmeier, S., Solorzano, A., Berlanda-Scorza, F., Innis, B.L., Garcia-Sastre, A., Palese, P., and Krammer, F. (2021). Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines, 9.","DOI":"10.3390\/vaccines9010040"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3389\/fimmu.2019.00756","article-title":"Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","article-title":"Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: Interim results of a randomised, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Bernstein","year":"2020","journal-title":"Lancet. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1128\/JVI.03562-13","article-title":"A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head","volume":"88","author":"Benjamin","year":"2014","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1128\/JVI.00420-14","article-title":"Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses","volume":"88","author":"Iba","year":"2014","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tsibane, T., Ekiert, D.C., Krause, J.C., Martinez, O., Crowe, J.E., Wilson, I.A., and Basler, C.F. (2012). Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1003067"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sun, W., Kirkpatrick, E., Ermler, M., Nachbagauer, R., Broecker, F., Krammer, F., and Palese, P. (2019). Development of Influenza B Universal Vaccine Candidates Using the \u201cMosaic\u201d Hemagglutinin Approach. J. Virol., 93.","DOI":"10.1128\/JVI.00333-19"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1128\/JVI.00730-16","article-title":"Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses","volume":"90","author":"Kamlangdee","year":"2016","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13300","DOI":"10.1128\/JVI.01532-14","article-title":"Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene","volume":"88","author":"Kamlangdee","year":"2014","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Corder, B.N., Bullard, B.L., DeBeauchamp, J.L., Ilyushina, N.A., Webby, R.J., and Weaver, E.A. (2019). Influenza H1 Mosaic Hemagglutinin Vaccine Induces Broad Immunity and Protection in Mice. Vaccines, 7.","DOI":"10.3390\/vaccines7040195"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-019-0126-4","article-title":"A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains","volume":"4","author":"Broecker","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1016\/j.vaccine.2019.06.077","article-title":"Effective mosaic-based nanovaccines against avian influenza in poultry","volume":"37","author":"Chandrasekar","year":"2019","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Florek, N.W., Kamlangdee, A., Mutschler, J.P., Kingstad-Bakke, B., Schultz-Darken, N., Broman, K.W., Osorio, J.E., and Friedrich, T.C. (2017). A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181738"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","article-title":"Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses","volume":"20","author":"Kanekiyo","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.vaccine.2011.01.100","article-title":"A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets","volume":"29","author":"Giles","year":"2011","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.03152-15","article-title":"Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses","volume":"90","author":"Carter","year":"2016","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jis232","article-title":"A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection","volume":"205","author":"Giles","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wong, T.M., Allen, J.D., Bebin-Blackwell, A.G., Carter, D.M., Alefantis, T., DiNapoli, J., Kleanthous, H., and Ross, T.M. (2017). Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants. J. Virol., 91.","DOI":"10.1128\/JVI.01581-17"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1080\/21645515.2019.1653743","article-title":"Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses","volume":"15","author":"Skarlupka","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79590-7","article-title":"Next generation methodology for updating HA vaccines against emerging human seasonal influenza A (H3N2) viruses","volume":"11","author":"Allen","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Reneer, Z.B., Jamieson, P.J., Skarlupka, A.L., Huang, Y., and Ross, T.M. (2020). Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges. J. Virol.","DOI":"10.1128\/JVI.01526-20"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.cell.2019.04.034","article-title":"\u201cBreathing\u201d Hemagglutinin Reveals Cryptic Epitopes for Universal Influenza Vaccine Design","volume":"177","author":"Wu","year":"2019","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","article-title":"A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface","volume":"177","author":"Bangaru","year":"2019","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2019.03.048","article-title":"Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism","volume":"177","author":"Watanabe","year":"2019","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"187ra170","DOI":"10.1126\/scitranslmed.3005996","article-title":"Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses","volume":"5","author":"Medina","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kosik, I., Ince, W.L., Gentles, L.E., Oler, A.J., Kosikova, M., Angel, M., Magadan, J.G., Xie, H., Brooke, C.B., and Yewdell, J.W. (2018). Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007141"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2015.08.033","article-title":"Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity","volume":"486","author":"Herve","year":"2015","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/JVI.02608-13","article-title":"Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain","volume":"88","author":"Eggink","year":"2014","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lin, S.C., Lin, Y.F., Chong, P., and Wu, S.C. (2012). Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039075"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lin, S.C., Liu, W.C., Jan, J.T., and Wu, S.C. (2014). Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092822"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/bit.26810","article-title":"Glycan-masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development","volume":"116","author":"Chen","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.chom.2019.04.003","article-title":"Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope","volume":"25","author":"Bajic","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.1617174114","article-title":"Influenza A surface glycosylation and vaccine design","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Kim, J.I., Park, S., Bae, J.Y., Lee, S., Kim, J., Kim, G., Yoo, K., Heo, J., Kim, Y.S., and Shin, J.S. (2020). Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3001024"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","article-title":"Influenza Virus Neuraminidase Structure and Functions","volume":"10","author":"McAuley","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1099\/vir.0.043059-0","article-title":"Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution","volume":"93","author":"Westgeest","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1128\/jvi.63.3.1239-1246.1989","article-title":"Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection","volume":"63","author":"Johansson","year":"1989","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/infdis\/jiv313","article-title":"Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination","volume":"212","author":"Petrie","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1126\/science.aay0678","article-title":"Broadly protective human antibodies that target the active site of influenza virus neuraminidase","volume":"366","author":"Stadlbauer","year":"2019","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.immuni.2020.08.015","article-title":"Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective","volume":"53","author":"Madsen","year":"2020","journal-title":"Immunity"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00705-016-2907-7","article-title":"Influenza virus neuraminidase (NA): A target for antivirals and vaccines","volume":"161","author":"Jagadesh","year":"2016","journal-title":"Arch. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.vaccine.2012.10.065","article-title":"Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines","volume":"31","author":"Couch","year":"2012","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"ofu115","DOI":"10.1093\/ofid\/ofu115","article-title":"Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel","volume":"2","author":"Thompson","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1128\/cdli.3.5.511-516.1996","article-title":"Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults","volume":"3","author":"Powers","year":"1996","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2018.03.025","article-title":"Neuraminidase as an influenza vaccine antigen: A low hanging fruit, ready for picking to improve vaccine effectiveness","volume":"53","author":"Eichelberger","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41564-017-0011-8","article-title":"Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes","volume":"2","author":"Wohlbold","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.antiviral.2013.09.018","article-title":"Universal anti-neuraminidase antibody inhibiting all influenza A subtypes","volume":"100","author":"Doyle","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e00560-19","DOI":"10.1128\/mBio.00560-19","article-title":"Mucosal immunity against neuraminidase prevents influenza B virus transmission in Guinea Pigs","volume":"10","author":"McMahon","year":"2019","journal-title":"mBio"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1099\/jgv.0.000809","article-title":"Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site","volume":"98","author":"Mogling","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12985-015-0295-3","article-title":"The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding","volume":"12","author":"Mohr","year":"2015","journal-title":"Virol. J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1128\/JVI.00458-10","article-title":"Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: A role in virus attachment?","volume":"84","author":"Lin","year":"2010","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1586\/erv.11.130","article-title":"Influenza viral neuraminidase: The forgotten antigen","volume":"10","author":"Johansson","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/infdis\/jiz017","article-title":"Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection","volume":"219","author":"Eichelberger","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.vaccine.2009.12.041","article-title":"A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects","volume":"28","author":"Cate","year":"2010","journal-title":"Vaccine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1128\/jvi.67.10.5721-5723.1993","article-title":"Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition","volume":"67","author":"Johansson","year":"1993","journal-title":"J. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1073\/pnas.84.19.6869","article-title":"Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins","volume":"84","author":"Johansson","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/iai.29.3.966-971.1980","article-title":"Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations","volume":"29","author":"Kendal","year":"1980","journal-title":"Infect. Immun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.vaccine.2014.01.078","article-title":"Stability of neuraminidase in inactivated influenza vaccines","volume":"32","author":"Sultana","year":"2014","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbamem.2010.04.015","article-title":"Influenza M2 proton channels","volume":"1808","author":"Pielak","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"13029","DOI":"10.1128\/JVI.01430-14","article-title":"Stepwise priming by acidic pH and a high K+ concentration is required for efficient uncoating of influenza A virus cores after penetration","volume":"88","author":"Stauffer","year":"2014","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2018.03.024","article-title":"Vaccine options for influenza: Thinking small","volume":"53","author":"Schepens","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4110\/in.2015.15.5.213","article-title":"Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ymthe.2017.01.010","article-title":"Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection","volume":"25","author":"Watkins","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kim, K.H., Kwon, Y.M., Lee, Y.T., Kim, M.C., Hwang, H.S., Ko, E.J., Lee, Y., Choi, H.J., and Kang, S.M. (2018). Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus. Vaccines, 6.","DOI":"10.3390\/vaccines6040066"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/mt.2012.246","article-title":"Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus","volume":"21","author":"Kim","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.virol.2012.04.015","article-title":"In contrast to conventional inactivated influenza vaccines, 4 \u00d7 M2e. HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran","volume":"430","author":"Ebrahimi","year":"2012","journal-title":"Virology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.vetmic.2014.09.009","article-title":"Vaccination with recombinant 4 \u00d7 M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens","volume":"174","author":"Dabaghian","year":"2014","journal-title":"Vet. Microbiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"316926","DOI":"10.1155\/2013\/316926","article-title":"A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens","volume":"2013","author":"Reese","year":"2013","journal-title":"Vet. Med. Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000319440","article-title":"Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens","volume":"54","author":"Zhang","year":"2011","journal-title":"Intervirology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2004.02.021","article-title":"Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys","volume":"22","author":"Fan","year":"2004","journal-title":"Vaccine"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14760584.2017.1240041","article-title":"M2-based influenza vaccines: Recent advances and clinical potential","volume":"16","author":"Kolpe","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","article-title":"Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults","volume":"29","author":"Turley","year":"2011","journal-title":"Vaccine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1099\/vir.0.029777-0","article-title":"Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes","volume":"92","author":"Doucet","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1016\/j.vaccine.2010.09.019","article-title":"Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant","volume":"28","author":"Sui","year":"2010","journal-title":"Vaccine"},{"key":"ref_118","first-page":"1","article-title":"Immunization with DNA prime-subunit protein boost strategy based on influenza H9N2 virus conserved matrix protein M1 and its epitope screening","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s15010-013-0546-4","article-title":"Development of universal influenza vaccines based on influenza virus M and NP genes","volume":"42","author":"Zheng","year":"2014","journal-title":"Infection"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-1991-3","article-title":"Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice","volume":"17","author":"Joe","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1080\/22221751.2020.1812436","article-title":"Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice","volume":"9","author":"Yin","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_122","first-page":"1","article-title":"OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes","volume":"4","author":"Pizzorno","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2020.05.085","article-title":"Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity","volume":"38","author":"Cookenham","year":"2020","journal-title":"Vaccine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.08.008","article-title":"Protection against influenza H7N9 virus challenge with a recombinant NP\u2013M1\u2013HSP60 protein vaccine construct in BALB\/c mice","volume":"111","author":"Yang","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/eji.201242922","article-title":"Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine","volume":"43","author":"Mullarkey","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_126","unstructured":"Vaccitech Limited (2021, January 15). Modified Vaccinia Virus Ankara (MVA) Vector Encoding NP and M1 (MVA-NP+M1) Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?recrs=&cond=MVA-NP%2BM1+&term=&cntry=&state=&city=&dist=."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Powell, T.J., Peng, Y., Berthoud, T.K., Blais, M.E., Lillie, P.J., Hill, A.V., Rowland-Jones, S.L., McMichael, A.J., Gilbert, S.C., and Dong, T. (2013). Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062778"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Antrobus, R.D., Lillie, P.J., Berthoud, T.K., Spencer, A.J., McLaren, J.E., Ladell, K., Lambe, T., Milicic, A., Price, D.A., and Hill, A.V. (2012). A T cell-inducing influenza vaccine for the elderly: Safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048322"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_132","unstructured":"Vaccitech Limited (2021, January 15). Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03880474."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2017.6.1.1","article-title":"Challenges in the development of T-cell-based universal influenza vaccines","volume":"6","author":"Kang","year":"2017","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1016\/j.vaccine.2019.07.095","article-title":"Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice","volume":"37","author":"Arunkumar","year":"2019","journal-title":"Vaccine"},{"key":"ref_136","first-page":"1","article-title":"Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin","volume":"11","author":"Park","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4014\/jmb.2011.11029","article-title":"Influenza chimeric protein (3M2e-3HA2-NP) adjuvanted with PGA\/alum conferred cross-protection against heterologous influenza A viruses","volume":"31","author":"Kwak","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10529-020-02822-3","article-title":"An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge","volume":"42","author":"Saleh","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Duarte, S.O., and Monteiro, G.A. (2021). Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031379"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21315\/mjms2020.27.2.2","article-title":"Multi-Epitope Peptide-Based and Vaccinia-Based Universal Influenza Vaccine Candidates Subjected to Clinical Trials","volume":"27","author":"Romeli","year":"2020","journal-title":"Malays. J. Med. Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1016\/j.vaccine.2014.08.031","article-title":"Priming by a novel universal influenza vaccine (Multimeric-001)\u2014A gateway for improving immune response in the elderly population","volume":"32","author":"Atsmon","year":"2014","journal-title":"Vaccine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.vaccine.2016.12.063","article-title":"Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011\/12 enhanced protective immune responses against 2014\/15 epidemic strain","volume":"35","author":"Lowell","year":"2017","journal-title":"Vaccine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e6339","DOI":"10.1097\/MD.0000000000006339","article-title":"Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine"},{"key":"ref_144","unstructured":"(2021, January 15). A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03450915."},{"key":"ref_145","unstructured":"(2021, January 15). Safety, Tolerability, Efficacy and Immunogenicity of an Influenza a Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02071329?term=FP-01.1&draw=2&rank=1."},{"key":"ref_146","unstructured":"(2021, January 15). A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza a Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01265914?term=NCT01265914&draw=2&rank=1."},{"key":"ref_147","unstructured":"(2021, January 15). Influenza A Vaccine (FP-01.1) Formulated with and without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01701752?term=FP-01.1&draw=2&rank=3."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.vaccine.2014.06.006","article-title":"A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety","volume":"33","author":"Francis","year":"2015","journal-title":"Vaccine"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2012.04.089","article-title":"Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial","volume":"30","author":"Pleguezuelos","year":"2012","journal-title":"Vaccine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/CVI.00098-15","article-title":"A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus challenge in humans","volume":"22","author":"Pleguezuelos","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/M19-0735","article-title":"Immunogenicity, safety, and efficacy of a standalone universal influenza vaccine, FLU-v, in healthy adults: A randomized clinical trial","volume":"172","author":"Pleguezuelos","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-0174-9","article-title":"Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study","volume":"5","author":"Pleguezuelos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted influenza vaccines","volume":"14","author":"Tregoning","year":"2018","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1016\/j.vaccine.2007.06.051","article-title":"In vitro interactions between macrophages and aluminum-containing adjuvants","volume":"25","author":"Rimaniol","year":"2007","journal-title":"Vaccine"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1016\/j.vaccine.2007.03.045","article-title":"Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants","volume":"25","author":"Sokolovska","year":"2007","journal-title":"Vaccine"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nm.2306","article-title":"Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity","volume":"17","author":"Flach","year":"2011","journal-title":"Nat. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0264-410X(02)00169-X","article-title":"Mechanisms of stimulation of the immune response by aluminum adjuvants","volume":"20","author":"HogenEsch","year":"2002","journal-title":"Vaccine"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"45951","DOI":"10.18632\/oncotarget.17504","article-title":"The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/sji.12208","article-title":"Evaluation of immune response elicited by inulin as an adjuvant with filarial antigens in mice model","volume":"80","author":"Mahalakshmi","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1128\/JVI.03030-12","article-title":"Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques","volume":"87","author":"Jegaskanda","year":"2013","journal-title":"J. Virol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Kommareddy, S., Singh, M., and O\u2019Hagan, D. (2017). MF59: A safe and potent adjuvant for human use. Immunopotentiators in Modern Vaccines, Elsevier.","DOI":"10.1016\/B978-0-12-804019-5.00013-X"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1385\/1-59259-083-7:211","article-title":"The adjuvant MF59: A 10-year perspective","volume":"42","author":"Ott","year":"2000","journal-title":"Vaccine Adjuv."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0264-410X(00)00499-0","article-title":"The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine","volume":"19","author":"Podda","year":"2001","journal-title":"Vaccine"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsps.2011.06.003","article-title":"Vaccine adjuvants\u2014Current status and prospects on controlled release adjuvancity","volume":"19","author":"Sivakumar","year":"2011","journal-title":"Saudi Pharm. J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: A review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses","volume":"31","author":"Moris","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"f794","DOI":"10.1136\/bmj.f794","article-title":"Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: Retrospective analysis","volume":"346","author":"Miller","year":"2013","journal-title":"BMJ"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., Himanen, S.L., Hublin, C., Julkunen, I., and Olsen, P. (2012). AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033536"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3389\/fimmu.2019.01604","article-title":"Poly-\u03b3-glutamic acid complexed with alum induces cross-protective immunity of pandemic H1N1 vaccine","volume":"10","author":"Nguyen","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/6\/973\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:03Z","timestamp":1760162823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/6\/973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":172,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["v13060973"],"URL":"https:\/\/doi.org\/10.3390\/v13060973","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]}}}